GlassScriptPhysician profile
Robert J Koch
NPI 1962497974
$297,893.10
in general payments reported to CMS, 2019-2025
52 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $50K · 2021: $30K · 2022: $35K · 2023: $38K · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $7,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,485.00 |
| Food and Beverage | $7,895.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136,748.46 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $88,621.31 | 2019-2023 | |
| Lilly USA, LLC | $39,749.48 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $17,787.75 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $1,927.65 | 2019-2025 | Xarelto, Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $1,656.27 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $1,390.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,346.71 | 2019-2025 | |
| Amgen INC. | $1,274.16 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $771.61 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $621.84 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Biotronik INC. | $522.86 | 2019-2021 | |
| Esperion Therapeutics, INC. | $485.47 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $480.20 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $472.55 | 2021-2025 | Verquvo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.